Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
Muneyoshi Kimura, Victor H. Ferreira, Sagar Kothari, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 10, pp. 706.e1-706.e10
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1699-1721
Closed Access | Times Cited: 28
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101983-101983
Open Access | Times Cited: 21
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 542-554
Closed Access | Times Cited: 8
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
Annalisa Ciabattini, G Pastore, Simone Lucchesi, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1706-1706
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1830-1830
Open Access | Times Cited: 16
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Jonathan Bordat, Sébastien Maury, Mathieu Leclerc
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
COVID‐19 in hematopoietic stem‐cell transplant recipients: A systematic review and meta‐analysis of clinical characteristics and outcomes
Bruno Azevedo Randi, Hermes Ryoiti Higashino, Vinícius Ponzio da Silva, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 6
Closed Access | Times Cited: 8
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
Ankit Mittal, Javier T Solera, Victor H. Ferreira, et al.
Transplantation and Cellular Therapy (2023) Vol. 29, Iss. 11, pp. 706.e1-706.e7
Open Access | Times Cited: 7
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Israel Henig, Jonathan Isenberg, Dana Yehudai‐Ofir, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 775-775
Open Access | Times Cited: 6
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study
Maryam Barkhordar, Bahram Chahardouli, Alireza Biglari, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
Annalisa Ciabattini, G Pastore, Simone Lucchesi, et al.
(2023)
Open Access | Times Cited: 6
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
Anna R. Giuliano, Barbara J. Kuter, Shari Pilon‐Thomas, et al.
Cancer Communications (2023) Vol. 43, Iss. 7, pp. 749-764
Open Access | Times Cited: 6
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation
Marie Luise Hütter‐Krönke, Adela Neagoie, Igor Wolfgang Blau, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun, Karan Srisurapanont, Kasama Manothummetha, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5624-5636
Open Access | Times Cited: 4
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
Béatrice Clémenceau, Amandine Le Bourgeois, Thierry Guillaume, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3010-3010
Open Access | Times Cited: 6
SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?
José Luís Piñana, Manuel Guerreiro, Carlos Solano
Hemato (2023) Vol. 4, Iss. 2, pp. 170-183
Open Access | Times Cited: 3
Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression
Shivaprasad Manjappa, Huy Q. Phi, Lik Wee Lee, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 11, pp. 784.e1-784.e9
Open Access | Times Cited: 4
Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients
Joe S. Al-Ramahi, Moazzam Shahzad, Kevin Li, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 12, pp. 1981-1991
Closed Access | Times Cited: 2
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top